SG11201609084QA - Hdl therapy markers - Google Patents

Hdl therapy markers

Info

Publication number
SG11201609084QA
SG11201609084QA SG11201609084QA SG11201609084QA SG11201609084QA SG 11201609084Q A SG11201609084Q A SG 11201609084QA SG 11201609084Q A SG11201609084Q A SG 11201609084QA SG 11201609084Q A SG11201609084Q A SG 11201609084QA SG 11201609084Q A SG11201609084Q A SG 11201609084QA
Authority
SG
Singapore
Prior art keywords
hdl therapy
therapy markers
markers
hdl
therapy
Prior art date
Application number
SG11201609084QA
Inventor
Jean-Louis Dasseux
Ronald Barbaras
Original Assignee
Cerenis Therapeutics Holding Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerenis Therapeutics Holding Sa filed Critical Cerenis Therapeutics Holding Sa
Publication of SG11201609084QA publication Critical patent/SG11201609084QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
SG11201609084QA 2014-05-02 2015-04-30 Hdl therapy markers SG11201609084QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461988095P 2014-05-02 2014-05-02
PCT/IB2015/000854 WO2015173633A2 (en) 2014-05-02 2015-04-30 Hdl therapy markers

Publications (1)

Publication Number Publication Date
SG11201609084QA true SG11201609084QA (en) 2016-11-29

Family

ID=54147231

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201609084QA SG11201609084QA (en) 2014-05-02 2015-04-30 Hdl therapy markers

Country Status (14)

Country Link
US (2) US20150316566A1 (en)
EP (1) EP3137899A2 (en)
JP (1) JP2017515893A (en)
KR (1) KR20170003611A (en)
CN (1) CN106488987A (en)
AU (1) AU2015260929A1 (en)
BR (1) BR112016025470A2 (en)
CA (1) CA2947127A1 (en)
IL (1) IL248601A0 (en)
MX (1) MX2016014306A (en)
PH (1) PH12016502167A1 (en)
RU (1) RU2016144908A (en)
SG (1) SG11201609084QA (en)
WO (1) WO2015173633A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11840707B2 (en) * 2016-05-31 2023-12-12 Institut De Cardiologie De Montreal Co-culture system and method for in vitro assessment of reverse cholesterol transport
WO2018029505A1 (en) * 2016-08-11 2018-02-15 Cerenis Therapeutics Holding Sa Cer-001 therapy for treating familial primary hypoalphalipoproteinemia
ES2681124B1 (en) * 2017-03-08 2019-06-19 Fund Imdea Alimentacion MEDICAL USES OF APOLIPOPROTEIN A AND ACTIVATORS OF THE SAME
CN108913761B (en) * 2017-08-10 2022-01-18 施军平 Kit for screening hereditary liver diseases
WO2019043201A1 (en) * 2017-09-01 2019-03-07 Sorbonne Universite Transcription factor znf471 as a therapeutic agent and a biomarker
CN107764890B (en) * 2017-10-16 2019-12-17 杭州先导医药科技有限责任公司 Method for distinguishing and detecting ezetimibe enantiomers
WO2020185598A1 (en) * 2019-03-08 2020-09-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for assessing cardiovascular disease or inflammatory disease risk using non-exchangeable lipid probe
CN112442114A (en) * 2019-08-29 2021-03-05 渥太华Hdl药物研发公司 Polypeptide and application thereof
WO2021209823A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein- based complexes
AU2021254856A1 (en) * 2020-04-16 2022-11-10 Abionyx Pharma Sa CER-001 therapy for treating kidney disease
WO2021209808A1 (en) * 2020-04-16 2021-10-21 Abionyx Pharma Sa Cer-001 therapy for treating kidney disease
CN116322646A (en) 2020-10-01 2023-06-23 阿比奥尼克斯制药公司 Compositions comprising lipid binding protein-based complexes for the treatment of ocular diseases
EP4322746A1 (en) 2021-04-15 2024-02-21 Abionyx Pharma SA Use of lipid binding protein-based complexes in organ preservation solutions
CN113332423A (en) * 2021-05-26 2021-09-03 华中科技大学同济医学院附属协和医院 Application of PCSK9 inhibitor in anti-rejection reaction after heart transplantation
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US5220043A (en) 1991-03-21 1993-06-15 Ohio University Synthesis of D-erythro-sphingomyelins
SE9103701D0 (en) 1991-12-13 1991-12-13 Kabi Pharmacia Ab apolipoprotein
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
SE9203753D0 (en) 1992-12-11 1992-12-11 Kabi Pharmacia Ab EXPRESSION SYSTEM FOR PRODUCING APOLIPOPROTEIN AI-M
FR2704556B1 (en) 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Recombinant viruses and their use in gene therapy.
EP0751961A1 (en) 1994-03-22 1997-01-08 Research Corporation Technologies, Inc. Eating suppressant peptides
US5932536A (en) 1994-06-14 1999-08-03 The Rockefeller University Compositions for neutralization of lipopolysaccharides
SE9500778D0 (en) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
US6258596B1 (en) 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
SE9603068D0 (en) 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (en) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
SE9603303D0 (en) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
AU777203B2 (en) 1998-12-30 2004-10-07 Hans Olof Johansson Separation method utilizing liquid-liquid partition
WO2000059855A1 (en) 1999-04-01 2000-10-12 Esperion Therapeutics, Inc. Ether compounds, compositions, and uses thereof
GB9919713D0 (en) 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
EP1278544A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
DE60117781T2 (en) 2000-04-21 2006-11-23 Amgen Inc., Thousand Oaks PEPTIDE DERIVATIVES OF APOLIPOPROTEIN-A1 / AII
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
EP1351916A2 (en) 2000-10-11 2003-10-15 Esperion Therapeutics Inc. Ether compounds and compositions for cholesterol management and related uses
CN1283610C (en) 2000-10-11 2006-11-08 埃斯佩里安医疗公司 Ketone compounds and compositions for cholesterol management and related uses
WO2002030882A2 (en) 2000-10-11 2002-04-18 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
BR0114619A (en) 2000-10-11 2005-12-13 Esperion Therapeutics Inc Compound, pharmaceutical composition, methods for treating or preventing cardiovascular disease, dyslipidemia, dyslipoproteinemia, glucose metabolism disorder, thrombotic and associated with peroxisome proliferator activated receptor, alzheimer's disease, x syndrome or metabolic syndrome , septicemia, obesity, pancreatitis, hypertension, kidney disease, cancer, inflammation and impotence, in a patient and to reduce the fat content of poultry eggs and poultry meat
US7304093B2 (en) 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
CN1268641C (en) 2000-11-10 2006-08-09 普罗蒂奥制药公司 Apolipoprotein analogues
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
US20060060520A1 (en) 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
WO2003000381A1 (en) 2001-06-25 2003-01-03 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
EP1425031B8 (en) 2001-08-20 2008-09-03 CSL Behring AG Hdl for the treatment of stroke and other ischemic conditions
AUPR798901A0 (en) 2001-09-28 2001-10-25 Medvet Science Pty. Ltd. Spheroidal hdl particles with a defined phospholipid composition
IL161110A0 (en) 2001-09-28 2004-08-31 Esperion Therapeutics Inc Prevention and treatment of restenosis by local admistration of drug
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
US7223726B2 (en) 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
US20040067873A1 (en) 2002-05-17 2004-04-08 Dasseux Jean-Louis H. Method of treating dyslipidemic disorders
AU2003254202A1 (en) 2002-07-30 2004-02-16 Esperion Therapeutics, Inc. Methods of using non-human animal apoliprotein a-i protein
SI2404890T1 (en) 2003-01-23 2017-12-29 Esperion Therapeutics Inc. Hydroxyl compounds and compositions for cholesterol management and related uses
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
WO2005011620A2 (en) 2003-07-03 2005-02-10 Lipid Sciences Inc. Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
DE602004020649D1 (en) 2003-11-07 2009-05-28 Jj Pharma Inc HDL REINFORCING COMBINATION THERAPY COMPLEXES
TW200526778A (en) 2003-11-14 2005-08-16 Sembiosys Genetics Inc Methods for the production of apolipoproteins in transgenic plants
EP1697746B1 (en) 2003-12-05 2012-02-22 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
WO2005058938A2 (en) 2003-12-15 2005-06-30 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
AU2003304703A1 (en) 2003-12-24 2005-08-03 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
KR100560102B1 (en) 2004-06-25 2006-03-13 한국생명공학연구원 Prophylactic and therapeutic agents containing point mutants of proapolipoprotein A-I for anti-atherosclerosis and anti-hyperlipidemia
US7378396B2 (en) 2004-08-11 2008-05-27 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
ATE469174T1 (en) 2004-10-15 2010-06-15 Us Gov Health & Human Serv AMPHIPATHIC HELIX-SHAPED MULTIDOMAIN PEPTIDES AND METHOD FOR USE THEREOF
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
EP2537526A1 (en) 2006-06-01 2012-12-26 Institut de Cardiologie de Montréal Method and compound for the treatment of valvular stenosis
WO2008021088A2 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
US8541236B2 (en) 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
ES2454966T3 (en) 2007-02-01 2014-04-14 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US7956035B2 (en) 2007-03-01 2011-06-07 Csl Limited Treatment of endothelial dysfunction in diabetic patients
US7749315B2 (en) 2007-04-04 2010-07-06 Xerox Corporation Phase change inks containing colorant compounds
SG183743A1 (en) 2007-08-17 2012-09-27 Csl Behring Gmbh Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
EP2195340A4 (en) 2007-08-28 2011-05-11 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
WO2009050275A1 (en) 2007-10-19 2009-04-23 Pronota N.V. A protease-sensitive site in apolipoprotein a1, therapeutic and diagnostic implications
EA201070517A1 (en) 2007-10-23 2010-12-30 Дзе Кливленд Клиник Фаундейшн SUSTAINABLE TO OXIDANTS OF APOLIPOPROTEIN A-1 AND PEPTIDE MIMETICS
WO2009155366A2 (en) 2008-06-18 2009-12-23 The Regents Of The University Of California Improved peptide mediators of cholesterol efflux
CA2982157A1 (en) 2009-02-16 2010-08-19 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
PL3431076T3 (en) 2009-06-10 2022-01-31 Arbutus Biopharma Corporation Improved lipid formulation
US20110152112A1 (en) * 2009-12-23 2011-06-23 Artery Therapeutics, Inc. Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases
CN103118683B (en) 2010-06-30 2015-08-19 杰特有限公司 RHDL preparation and production method thereof
SI2767546T1 (en) 2011-02-07 2019-03-29 Cerenis Therapeutics Holding Sa Lipoprotein complexes and manufacturing and uses therof

Also Published As

Publication number Publication date
WO2015173633A2 (en) 2015-11-19
BR112016025470A2 (en) 2017-08-15
EP3137899A2 (en) 2017-03-08
PH12016502167A1 (en) 2017-01-09
US20180203025A1 (en) 2018-07-19
WO2015173633A3 (en) 2016-01-21
MX2016014306A (en) 2017-06-12
KR20170003611A (en) 2017-01-09
JP2017515893A (en) 2017-06-15
RU2016144908A3 (en) 2018-12-18
CN106488987A (en) 2017-03-08
AU2015260929A1 (en) 2016-12-15
RU2016144908A (en) 2018-06-05
US20150316566A1 (en) 2015-11-05
IL248601A0 (en) 2016-12-29
CA2947127A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
IL248601A0 (en) Hdl therapy markers
HK1243073A1 (en) Therapeutic compounds and uses thereof
HUE051354T2 (en) Therapeutic
IL250387A0 (en) Combination therapy
GB201410816D0 (en) Therapeutic agents
GB201405033D0 (en) Combination therapy
GB201415569D0 (en) Therapeutic Compounds
IL247325A0 (en) Therapeutic methods employing noribogaine and related compounds
ZA201702522B (en) Combination therapy
GB201410216D0 (en) Therapeutic
GB201502412D0 (en) Therapeutic use
GB201410817D0 (en) Therapeutic agents
GB201410815D0 (en) Therapeutic agents
GB201416727D0 (en) Use
GB201416716D0 (en) Use
GB201510637D0 (en) Therapeutic
GB201416273D0 (en) Therapeutic compounds
ZA201608217B (en) Combination therapy
GB201506786D0 (en) Therapeutic use
GB201414542D0 (en) Novel therapy
GB201517698D0 (en) Velcro
GB201517685D0 (en) Velcro
GB201518805D0 (en) Therapy
GB201514285D0 (en) Velcro
GB201418508D0 (en) Therapeutic